Related Experiment Video
Updated: Feb 24, 2026

07:43
Immunohistochemical Visualization of Hippocampal Neuron Activity After Spatial Learning in a Mouse Model of Neurodevelopmental Disorders
Published on: May 12, 2015
11.9K
miR-181a involves in the hippocampus-dependent memory formation via targeting PRKAA1
Sun-Fu Zhang1,2, Jun-Chen Chen3, Jing Zhang1
1Department of Neurosurgery, West China Hospital, Sichuan University, Chengdu, Sichuan, P. R. China.
Scientific Reports
|August 18, 2017
Summary
MicroRNAs (miRNAs) regulate memory. This study shows miR-181a enhances hippocampus-dependent memory by targeting PRKAA1, offering insights into cognitive function and disorders.
Area of Science:
- Neuroscience
- Molecular Biology
- Genetics
Background:
- MicroRNAs (miRNAs) are key regulators of post-transcriptional gene expression.
- Their specific roles in hippocampus-dependent memory formation are not fully understood.
Purpose of the Study:
- To elucidate the function of miR-181a in hippocampus-dependent memory formation.
- To identify the molecular targets and mechanisms underlying miR-181a's role.
Main Methods:
- Conditioned fear conditioning (CFC) and object location task (OLT) in rodents.
- In vivo manipulation of miR-181a levels in the dorsal hippocampus (DH) using agomirs and antagomirs.
- Bioinformatic analysis, luciferase assays, and Western blotting to identify and validate miR-181a targets.
- Pharmacological manipulation of target gene activity in the DH.
Main Results:
- miR-181a expression transiently increased after CFC and OLT training.
- Overexpression of miR-181a enhanced memory, while inhibition impaired it.
- PRKAA1 was identified as a direct target of miR-181a, with its expression and activity inversely correlated with miR-181a levels.
- Modulation of PRKAA1 activity reversed the effects of miR-181a manipulation on memory.
Conclusions:
- miR-181a plays a critical role in hippocampus-dependent memory formation.
- The miR-181a/PRKAA1 pathway is a novel mechanism regulating memory.
- Findings suggest potential therapeutic targets for cognitive disorders.

